In the Alzheimer’s disease brain, the amyloid beta peptide clumps together to form hardened plaques between nerve cells.
University of South Florida Health neuroscientist suggests the therapeutic immunomodulatory vaccine may be safer for those with age-associated decline in immunity
Our immune system’s capacity to mount a well-regulated defense against foreign substances, including toxins, weakens with age and makes vaccines less effective in people over age 65. At the same time, research has shown that immunotherapy targeting neurotoxic forms of the peptide amyloid beta (oligomeric A?) may halt the progression of Alzheimer’s disease, the most common age-related neurodegenerative disease.
A team led by Chuanhai Cao, PhD, of the University of South Florida Health (USF Health), has focused on overcoming, in those with impaired immunity, excess inflammation and other complications that interfere with development of a therapeutic Alzheimer’s vaccine.
Now, a preclinical study by Dr. Cao and colleagues indicates that an antigen-presenting dendritic vaccine with a specific antibody response to oligomeric A? may be safer and offer clinical benefit in treating Alzheimer’s disease. The vaccine, called E22W42 DC, uses immune cells known as dendritic cells (DC) loaded with a modified A? peptide as the antigen.
The Alzheimer’s mouse model study of this new investigational vaccine was published early online Oct. 13 in the Journal of Alzheimer’s Disease.
One of the two hallmark pathologies of Alzheimer’s disease is hardened deposits of A? that clump together between nerve cells (amyloid protein plaques) in the brain; the other is neurofibrillary tangles of tau protein inside brain cells. Both lead to damaged neurological cell signaling, ultimately causing the onset of Alzheimer’s disease and symptoms.
“This therapeutic vaccine uses the body’s own immune cells to target the toxic A? molecules that accumulate harmfully in the brain,” said principal investigator Dr. Cao, a neuroscientist at the USF Health Taneja College of Pharmacy, USF Health Morsani College of Medicine and the university’s Byrd Alzheimer’s Center. “And, importantly, it provides strong immunomodulatory effects without inducing an unwanted, vaccine-associated autoimmune reaction in the aging mice.”
Unfortunately, clinical trials of all anti-amyloid treatments for Alzheimer’s disease so far have failed – including the initial vaccine trial targeting A? (AN-1792), which was suspended in 2002 after several immunized patients developed central nervous system inflammation. “Inflammation is a primary symptom of Alzheimer’s disease, so any possible treatment which has neural inflammation as a side effect essentially pours gas on the fire,” Dr. Cao said.
A next-generation anti-amyloid vaccine for Alzheimer’s would ideally produce long-lasting, moderate antibody levels needed to prevent A? oligomers from further aggregating into destructive Alzheimer’s plaques, without over-stimulating the immune systems of elderly people, Dr. Cao added.
In this study, the researchers tested the vaccine they formulated using modified A?-sensitized dendritic cells derived from mouse bone marrow. Dendritic cells interact with other immune cells (T-cells and B-cells) to help regulate immunity, including suppressing harmful responses against healthy tissues. “Because we use dendritic cells to generate antibodies, this vaccine can coordinate both innate and acquired immunity to potentially overcome age-related impairments of the immune system,” Dr. Cao said.
The study included three groups of transgenic (APP/PS1) mice genetically engineered to develop high levels of A? and behavioral/cognitive abnormalities that mimic human Alzheimer’s disease. One group was vaccinated with the investigational E22W42 DC vaccine, another received an endogenous amyloid beta peptide to stimulate dendritic cells (wild-type vaccine group), and the third was injected with dendritic cells only, containing no A? peptide (DC control group). A fourth group was comprised of untreated healthy, older mice (nontransgenic control group).
Among the study findings:
– The vaccine slowed memory impairment in the Alzheimer’s transgenic mice, with mice in the E22W42 DC vaccinated group demonstrating memory performance similar to that of the nontransgenic, untreated mice. In a cognitive test called a radial arm water maze, the E22W42 DC-vaccinated mice also showed significantly less errors in working memory than the mice injected with non-sensitized dendritic cells only (DC controls). Loss of working memory makes it difficult to learn and retain new information, a characteristic of Alzheimer’s disease.
– No significant differences were found in the quantities of inflammatory cytokines measured in the plasma of the vaccinated mice, versus amounts in the control mice. The researchers concluded that the E22W42 DC vaccine has “little potential for over priming the immune system.”
– E22W42 DC-vaccinated mice showed higher levels of anti-A? antibodies in both in their brain and in their blood than the transgenic control mice administered dendritic cells containing no modified A? peptide.
– Only A? peptides with mutations introduced in the T-cell epitope (the distinct surface region of the antigen where complementary antibodies bind) can sensitize the dendritic cells to target toxic oligomeric forms of A?, the researchers reported. A major advantage of E22W42 is that the antigen can stimulate a specific T-cell response that activates the immune system and silence some T-cell epitopes associated with an autoimmune response, they added.
“Though the E22W42-sensitized DC vaccine is being developed for patients with Alzheimer’s disease, it can potentially help strengthen the immune system of elderly patients (with other age-related disorders) as well,” the study authors concluded.
Dr. Cao conducted the study with collaborators from Tianjin University of Traditional Chinese Medicine and Michigan State University.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- 5 for Good: Norwell residents with memory loss raise money to fight Alzheimer's disease
Residents at the Cordwainer in Norwell, a community for people with memory loss, are raising money for the Alzheimer's Association.
- Study reveals a complex interplay of genetic and epigenetic changes in Alzheimer’s disease progression
Alzheimer's disease affects more than 6 million people in the United States, and there are very few FDA-approved treatments that can slow the progression of the disease.
- Decoding the complexity of Alzheimer's disease
Alzheimer's disease affects more than 6 million people in the United States, and there are very few FDA-approved treatments that can slow the progression of the disease. In hopes of discovering new targets for potential Alzheimer's treatments, MIT ...
- These 3 Simple Tests Could Show If You're at Risk of Alzheimer's Disease
Alzheimer's is a disease that affects a significant section of the population. Most people have likely had interactions with a friend, relative, or acquaintance suffering from the condition, which currently affects over 6 million Americans.
- Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
Roche gains exclusive worldwide rights to develop, manufacture and commercialize the investigational medicines discovered by IonisIonis to
Go deeper with Google Headlines on:
[google_news title=”” keyword=”Alzheimer’s disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- 27 Exciting New Restaurants Coming to the DC Area
Hakan Ilhan—also behind DC’s Ottoman Taverna and Il Piatto—is turning the Paolo’s space in Georgetown into an all-day Mediterranean dining room. When it opens in February, the cuisines of Greece, ...
- Washington, DC
The District of Columbia, located on the north bank of the Potomac River, is the capital city of United States. The centers of all three branches of the U.S. federal government are located in the ...
- Kingdom Come - the iconic DC mega-hit explained
Last week DC revealed that the next issue of World's Finest will be taking a trip back to the universe of Kingdom Come. Batman/Superman: World's Finest #20 is the start of a five-issue arc ...
- Upcoming Superhero Movies: Marvel, DC And More
The superhero movie genre is not going anywhere! There are plenty more comic book movies like those to look forward to on our upcoming 2024 movies schedule and even further into the foreseeable ...
- DC's Next Comic Event is An Attack of The Fursonas
For Marvel and DC, event comics are intended as a good way to get readers attention once or twice (or more) per year. Some events clear the deck so a new status quo can be put in place for a year ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”E22W42 DC” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]